Pfizer halts study of lymphoma drug unlikely to help survival

(Reuters) – Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival. Pfizer said it would continue to study the experimental drug, inotuzumab ozogamicin, in other hematologic cancers. …